Northern Trust Corp Lowers Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

Northern Trust Corp lowered its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 18.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,141,992 shares of the company's stock after selling 251,587 shares during the quarter. Northern Trust Corp owned 0.92% of Guardant Health worth $34,888,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Guyasuta Investment Advisors Inc. acquired a new position in shares of Guardant Health during the fourth quarter valued at $206,000. Entropy Technologies LP acquired a new position in Guardant Health in the fourth quarter valued at about $377,000. Stifel Financial Corp lifted its stake in Guardant Health by 25.1% in the fourth quarter. Stifel Financial Corp now owns 49,927 shares of the company's stock valued at $1,525,000 after buying an additional 10,006 shares during the period. Raymond James Financial Inc. bought a new position in Guardant Health during the fourth quarter worth about $2,211,000. Finally, Swiss National Bank increased its stake in shares of Guardant Health by 1.0% in the 4th quarter. Swiss National Bank now owns 241,900 shares of the company's stock valued at $7,390,000 after acquiring an additional 2,500 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at $107,952,954.72. This represents a 4.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 107,132 shares of company stock valued at $5,249,355 in the last quarter. Insiders own 5.50% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on GH. Scotiabank reaffirmed an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. UBS Group lifted their price target on Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $60.00 target price (up previously from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Stifel Nicolaus boosted their price target on Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Finally, JPMorgan Chase & Co. upped their price objective on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Twenty-one analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $52.32.

Guardant Health Price Performance

NASDAQ GH traded down $0.30 during trading hours on Tuesday, reaching $41.36. The company's stock had a trading volume of 1,492,842 shares, compared to its average volume of 2,203,651. The firm has a fifty day simple moving average of $43.70 and a 200-day simple moving average of $39.24. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $52.92. The stock has a market cap of $5.12 billion, a P/E ratio of -11.62 and a beta of 1.49.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. During the same period in the prior year, the business posted ($0.46) earnings per share. The company's quarterly revenue was up 20.8% compared to the same quarter last year. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.